Document is current
Any future updates will be listed below
-
Authors
Kaplan, Lee M. https://orcid.org/0000-0002-6301-2696
Startseva, Elena https://orcid.org/0000-0002-9363-7056
le Roux, Carel W. https://orcid.org/0000-0001-5521-5445
Wharton, Sean
Bozkurt, Biykem https://orcid.org/0000-0002-6362-0253
Mazo, Daniel F. https://orcid.org/0000-0002-2164-2630
von Schlippenbach, Jessica
González Maldonado, Sandra
Ajaz Hussain, Samina https://orcid.org/0009-0002-4849-0363
Neff, Guy W.
Gonzalez Rojas, Yaneicy
Smith, Charles
Younes, Ramy
Sanyal, Arun J. https://orcid.org/0000-0001-8682-5748
,
Martin, Antonio O.
Leibowitz, Mark
Denham, Douglas
Korenblat, Kevin
Herman, Michael
Challa, Shekhar
Youssef, Rasha
Khaja, Masi
Vutikullird, Apinya
Aguilar, Humberto
Chalasani, Naga
Maher, James
Surowitz, Ronald
Steimle, Cassandra
Rojas, Yaneicy G.
Sanchez, Antonio
Kavcioglu, Ruth E.
Vijil, Julio
Perry, Robert
Neff, Guy
Navarro, Martha G.
Khalid, Omer
Mohseni, Rizwana
Vu, Julie
Lucksinger, Gregg
Iduru, Satish
Shuster, Dmitry
Segal, Bruce
Hellstern, Paul
- License Information
-
More Information
Article History
Received: 24 April 2026
Accepted: 21 May 2026
First Online: 7 June 2026
Competing interests
: The authors did not receive payment related to the development of the manuscript. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations. Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally. L.M.K. has served as a scientific and medical consultant to Altimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Dexligo, Dil Figaro, Eli Lilly, Helicore, Johnson & Johnson, Kallyope, The Last Food Fight, MetaVia, Neurogastrx, Novo Nordisk, Optum Health, Oxford Medical Products, Perspectum, Pfizer, Roche/Genentech, Skye Bioscience, State 4 Therapeutics, Structure Therapeutics and Wave Life Sciences. C.l.R. has received personal fees from Boehringer Ingelheim, Eli Lilly, GI Dynamics, Herbalife, Johnson & Johnson, Keyron and Novo Nordisk, outside the submitted work. S.W. has conducted multicenter trials with Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Pfizer and Roche; serves on scientific advisory boards for AbbVie, Amgen, AstraZeneca, Bausch Health Canada, Boehringer Ingelheim, Eli Lilly, i2o Therapeutics, Merck, Metsera, NGX, Novo Nordisk and Regeneron; and receives institutional grant funding from the Canadian Institutes of Health Research. B.B. has served as a consultant or advisor for ABIOMED/Johnson & Johnson, Bayer, Boehringer Ingelheim, Cardurion, Cytokinetics, Eli Lilly, Idorsia, Medtronic, Merck, Novo Nordisk, Regeneron, Renovacor, Roche, Salubris, Sanofi-Aventis, scPharmaceuticals, Respicardia/Zoll and Vifor. G.W.N. received research grant support from Akero, Allergan, Altimmune, Bristol Myers Squibb, Boehringer Ingelheim, Boston Pharma, Corcept, Genfit, Gilead, GlaxoSmithKline, Eli Lilly, Madrigal, Merck, Novartis, Novo Nordisk and Takeda and consulted for Boehringer Ingelheim and Intercept Pharmaceuticals. A.J.S. has stock options for Durect, NorthSea, Rivus and Tiziana; has consulted for 89Bio, AbbVie, Akero, Aligos, Alnylam, Altimmune, Amgen, AstraZeneca, Avant Sante, Boehringer Ingelheim, Boston Pharma, Chemomab, Corcept, Eli Lilly, Genentech, Genfit, GlaxoSmithKline, Hanmi, Histoindex, Intercept, Inventiva, Madrigal, Malinckrodt, Medscape, Merck, Myovant, Novo Nordisk, Pliant, Poxel, Regeneron, Sagimet, Salix, Surrozen and Takeda; has received research grants to the institution from 89Bio, Gilead, Hanmi, Intercept, Madrigal, Merck, Novo Nordisk and Salix; and receives royalties from Elsevier and UpToDate. E.S., D.F.M., J.v.S., S.G.M., S.A.H. and R.Y. are employees of Boehringer Ingelheim. The remaining authors declare no competing interests.
